A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This 6 arm study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of
multiple doses and regimens of a GLP-1 analogue in patients with type 2 diabetes who are
treated with a stable dose of metformin. Patients will be randomized to receive either
subcutaneous placebo, or subcutaneous GLP-1 analogue, 5mg, 10mg or 20mg weekly, or 10mg or
20mg every 2 weeks. All patients will continue on their existing metformin treatment regimen
throughout the study. The anticipated time on study treatment is <3 months, and the target
sample size is 100-500 individuals.